Cargando…

High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases

A retrospective review was performed on patients with stable melanoma brain metastases treated with HD IL-2 therapy (720,000 IU/kg per dose intravenously; 14 doses, 2 cycles per course, maximum 2 courses) from January 1999 to June 2011 at Saint Louis University. There were 5 men and 3 women; median...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chu, Melinda B., Fesler, Mark J., Armbrecht, Eric S., Fosko, Scott W., Hsueh, Eddy, Richart, John M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666432/ https://www.ncbi.nlm.nih.gov/pubmed/23762555 http://dx.doi.org/10.1155/2013/726925

Ejemplares similares

Complete metastasectomy after high-dose interleukin-2 (HD IL-2) therapy for melanoma
por: Chu, Melinda, et al.
Publicado: (2015)

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
por: Buchbinder, Elizabeth I., et al.
Publicado: (2016)

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
por: Buchbinder, Elizabeth I., et al.
Publicado: (2019)

Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2
por: Kaufman, Howard L, et al.
Publicado: (2014)

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute
por: Davar, Diwakar, et al.
Publicado: (2017)

Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)
por: Clark, Joseph I, et al.
Publicado: (2015)

The role of surgery following incomplete response to high-dose IL-2 (HD IL-2)
por: Hughes, Tasha, et al.
Publicado: (2013)

Melanoma of unknown primary in the pancreas: should it be considered primary?
por: Jin, Yanwen, et al.
Publicado: (2020)

Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2
por: Wong, Michael KK, et al.
Publicado: (2015)

Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients
por: Posch, C, et al.
Publicado: (2014)

Evaluation of the Definitions of “High-Risk” Cutaneous Squamous Cell Carcinoma Using the American Joint Committee on Cancer Staging Criteria and National Comprehensive Cancer Network Guidelines
por: Chu, Melinda B., et al.
Publicado: (2014)

Clinical benefit of high dose IL-2 (HD IL-2) therapy: evidence for improved overall survival in patients with stable disease
por: Hughes, Tasha, et al.
Publicado: (2013)

Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases
por: Radny, P, et al.
Publicado: (2003)

Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases?
por: Lee, Rachael Chang, et al.
Publicado: (2018)

Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. III: Cytokine studies.
por: Haworth, C., et al.
Publicado: (1993)

Should Abdominoperineal Excision Be Considered as the Initial Treatment for a Primary Anorectal Malignant Melanoma?
por: Oh, Jae Hwan
Publicado: (2011)

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM(SM) registry
por: Fishman, M., et al.
Publicado: (2019)

Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in patients with metastatic melanoma (proclivity 02)
por: Patel, Sapna, et al.
Publicado: (2014)

Para-aortic lymph node metastases in pancreatic cancer should not be considered a watershed for curative resection
por: Hempel, Sebastian, et al.
Publicado: (2017)

High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection
por: Chow, Shien, et al.
Publicado: (2014)

Interleukin 11 (IL-11): Role(s) in Breast Cancer Bone Metastases
por: Maroni, Paola, et al.
Publicado: (2021)

The Security of People Should Be Considered First
por: Chung, Min Suk
Publicado: (2020)

Treatment of melanoma in-transit metastases with combination intralesional interleukin-2, topical imiquimod, and tretinoin 0.1% cream
por: Leventhal, Jonathan S., et al.
Publicado: (2016)

A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (proclivity 01)
por: Clark, Joseph, et al.
Publicado: (2014)

Effects of Hd2 in the presence of the photoperiod-insensitive functional allele of Hd1 in rice
por: Zhang, Zhen-Hua, et al.
Publicado: (2016)

High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma
por: Silk, Ann W., et al.
Publicado: (2020)

Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: immunological studies.
por: Ghosh, A. K., et al.
Publicado: (1990)

Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD
por: Ashami, Kidist, et al.
Publicado: (2018)

Should the left gastric artery lymph node be considered as the predictive lymph node for extra-gastric lymph node metastases?
por: Sun, Weilin, et al.
Publicado: (2020)

What the neuroradiologist should additionally consider in SARS-CoV-2 infection
por: Finsterer, J., et al.
Publicado: (2020)

Reactions of H(2), HD, and D(2) with H(2)(+), HD(+), and D(2)(+): Product-Channel Branching Ratios and Simple Models
por: Merkt, Frédéric, et al.
Publicado: (2022)

Novel melanoma therapy
por: Hsueh, Eddy C., et al.
Publicado: (2016)

Why should Cannabis be Considered Doping in Sports?
por: Bergamaschi, Mateus M., et al.
Publicado: (2013)

Emergent Colorectal Surgery: What Should Be Considered?
por: Kim, Chang-Nam
Publicado: (2016)

Depression in the older adult: What should be considered?
por: Bradley, Bridget, et al.
Publicado: (2016)

Who Should Be Considered for Islet Transplantation Alone?
por: Othonos, Nantia, et al.
Publicado: (2017)

Methodological notes, should be considered in research on mizaj
por: Farahani, Akram Moradi, et al.
Publicado: (2021)

Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration
por: Panelli, Monica C, et al.
Publicado: (2002)

Associations of Fc gamma receptor (FcgR2a, FcgR3a and FcgR2c) genotype with outcome in metastatic renal cell carcinoma (mRCC) patients receiving high dose interleukin 2 (HD-IL2)
por: Erbe, Amy K, et al.
Publicado: (2015)

Simultaneous primary invasive breast carcinoma and ipsilateral cutaneous melanoma of the back: Surgical approach and considerations, a case report
por: Fosko, Nicole K., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cepkd7q938v1r220pgm1268de3